Table 2.
Patient, disease, and treatment characteristics
| References | Group | Age (years) | ASA | T4a/T4b | N+-stage | M1-stage | Neoadjuvant therapy | Adjuvant chemotherapy |
|---|---|---|---|---|---|---|---|---|
| De’Angelis et al. [11] | Lap (n = 106) Open (n = 106) |
Median: 71 (18–94) Median: 76 (27–91) p = 0.208 |
≥3: 24 (23%) ≥3: 30 (28%) p = 0.516 |
pT4a: 91 (86%) pT4b: 15 (14%) pT4a: 86 (81%) pT4b: 20 (19%) p = 0.460 |
61 (58%) 66 (62%) p = 0.573 |
0 0 |
NR | 63 (59%) 53 (50%) p = 0.214 |
| Chan et al. [12] | Lap (n = 93) Open (n = 59) |
NS | NS | NR | 54 (58%) 46 (78%) p = 0.012 |
NS | NR | NR |
| Elnahas et al. [13] | Lap (n = 455) Open (n = 406) |
67 (SD 14) 67 (SD 15) p = 0.92 |
≥3: 27 (6.3%) ≥3: 28 (7.1%) p = 0.64 |
T4a only | 296 (69%) 268 (69%) p = 0.99 |
122 (28%) 111 (28%) p = 0.98 |
20 (4.6%) 19 (4.7%) p = 0.94 |
NR |
| Kang et al. [14] | Lap (n = 52) Open (n = 57) |
62 (SD 14) 65 (SD 12) |
≥3: 8 (15%) ≥3: 3 (5.3%) |
pT4a: 45 (87%)pT4b: 7 (14%) pT4a: 39 (69%)pT4b: 18 (32%) p = 0.025 |
35 (67%) 33 (58%) p = 0.577 |
0 0 |
NR | 42 (81%) 43 (75%) p = 0.502 |
| Kim et al. [15] | Lap (n = 51) Open (n = 66) |
70 (SD 12) 67 (SD 11) p = 0.181 |
≥3: 4 (7.8%) ≥3: 11 (17%) p = 0.110 |
pT4a: 49 (96%) pT4b: 2 (3.9%) pT4a: 54 (82%) pT4b: 12 (18%) p = 0.018 |
34 (67%) 40 (61%) p = 0.468 |
0 0 |
NR | NR NR |
| Nagasue et al. [16] | Lap (n = 39) Open (n = 53) |
65 (SD 13) 64 (SD 13) p = 0.843 |
NR | pT1-3: 9 (23%) pT4a: 7 (18%) pT4b: 23 (59%) pT1-3: 12 (23%) pT4a: 4 (7.5%) pT4b: 37 (70%) p = 0.275 |
27 (69%) 21 (39%) p = 0.005 |
15 (39%) 10 (19%) p = 0.037 |
0 (0%) 2 (3.8%) p = 0.506 |
15 (63%) (M0 only (n = 24)) 16 (37%) (M0 only (n = 43)) p = 0.047 |
| Park et al. [17] | Lap (n = 71) Open (n = 222) |
Median: 59 (36–80) Median: 61 (17–84) p = 0.321 |
≥2: 38 (54%) ≥2: 132 (60%) p = 0.377 |
cT4a: 58 (82%) cT4b: 13 (18%) cT4a: 130 (59%) cT4b: 92 (41%) p < 0.001 |
43 (61%) 104 (47%) p = 0.085 |
0 0 |
0 0 |
60 (85%) 171 (77%) p = 0.179 |
| Sammour et al. [18] | Lap (n = 89) Open (n = 184) |
67 (SD 14) 67 (SD 14) p = 0.540 |
26 (48%)* 53 (44%) p = 0.626 |
pT4a: 48 (81%)*pT4b: 11(19%) pT4a: 80 (67%)pT4b: 40 (33%) p = 0.041 |
66 (74%)* 135 (74%) p = 0.997 |
26 (29%)* 65 (36%) p = 0.301 |
0 (0%) 3 (1.6%) p = 0.553 |
40 (64%) (M0 only (n = 63)) 65 (55%) (M0 only (n = 118)) p = 0.275 |
| Shukla et al. [19] | Lap (n = 61) Open (n = 22) |
Median: 70 (31–88) Median: 71 (35–93) p = 0.680 |
≥3: 27 (44%) ≥3:10 (46%) 0.923 |
pT4a: 53 (87%) pT4b: 8 (13%) pT4a: 15 (68%) pT4b: 7 (32%) p = 0.102 |
37 (61%) 11 (50%) p = 0.667 |
0 0 |
1 (1.6%) 2 (9.0%) p = 0.170 |
53 (87%) 16 (73%) p = 0.182 |
| Takahashi et al. [20] | Lap (n = 48) Open (n = 36) |
Median: 69 (49–86) Median: 62 (46–88) p = 0.135 |
PS≥1: 11 (23%) PS≥1: 16 (44%) p = 0.037 |
pT4b: 22 (46%) pT4b: 20 (56%) p = 0.378 |
14 (29%) 7 (19%) p = 0.397 |
13 (27%) 8 (22%) p = 0.397 |
(6.3%) (25%) p = 0.015 |
10 (71% of stage III) 4 (57% of stage III) |
| Vallribera Valls et al. [21] | Lap (n = 69) Open (n = 76) |
71 (SD 12) 70 (SD 12) p = 0.612 |
≥3: 24 (35%) ≥3: 20 (26%) p = 0.268 |
41 (59%) 43 (58%) p = 0.873 |
0 0 |
NR | NR | |
| Vignali et al. [22] | Lap Open |
65 (SD 13) 64 (SD 21) p = 0.21 |
Mean: 1.94 (SD 0.4) Mean: 1.94 (SD 0.6) p = 0.88 |
pT4a: 52 (74%) pT4b: 18 (26%) pT4a: 46 (66%) pT4b: 24 (34%) p = 0.49 |
32 (46%) 32 (46%) p = 0.55 |
5 (7.1%) 5 (7.1%) p = 0.55 |
0 (0%) 0 (0%) |
52 (74%) 56 (80%) p = 0.66 |
| Allaix et al. [23] | Lap (n = 13) | Mean: 60 (7.8) | NR | NR. Mainly T4a, since organ invasion on preoperative imaging was an exclusion criteria | 10 (77%) | 0 | NR | 12 (92%) |
Age is displayed in median (range) or mean (SD)
Lap laparoscopic surgery; NR not reported; Open open surgery; PS performance status
* Excluding missing cases